NASDAQ:JAZZ

Jazz Pharmaceuticals Stock News

etoro logo Buy JAZZ
*Your capital is at risk
$230.93
+4.81 (+2.13%)
At Close: Jun 03, 2026
DUBLIN , Sept. 4, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced the pricing of $850 million aggregate principal amount of 3.125% exchangeable s
DUBLIN , Sept. 3, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), int
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
DUBLIN , Aug. 22, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 3 open-label, single-arm trial in Japan evaluating the safety and effica
DUBLIN , Aug. 21, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: Wells Fargo Healthcare C
Investors with an interest in Medical - Drugs stocks have likely encountered both Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT). But which of these two companies is the best option for those looking
The consensus price target hints at a 56.7% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate rev
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Cannabis stocks initially sounded like a compelling opportunity when Canada became the first G7 nation to legalize recreational marijuana. At the time, the popular belief was that the U.S. would event
Review Jazz's (JAZZ) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Jazz's (JAZZ) reports better-than-expected second quarter results. While it revises its guidance for 2024, it withdraws the financial guidance issued as part of the Vision 2025 plan.
Jazz Pharmaceuticals plc. (NASDAQ:JAZZ ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Andrea Flynn - Vice President and Head-Investor Relations Bruce Cozadd - Chairma
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $5.30 per share, beating the Zacks Consensus Estimate of $4.68 per share. This compares to earnings of $4.51 per share a year ago.
– 15% year-over-year revenue increase from combined key growth drivers: Xywav®, Epidiolex® and Rylaze® –– Oncology revenues grew 10% year-over-year –– Zanidatamab granted Priority Review

3 Biotech Stocks to Buy on the Dip: July 2024

06:00am, Monday, 29'th Jul 2024
The biotechnology sector doesn't need to rizz up investors, as the kids like to say. Unless the human desire to find solutions for vexing conditions and diseases somehow goes away in a dystopian parad
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE